12:00 AM
 | 
Jun 09, 2014
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Altiratinib: Phase I started

Deciphera began a 2-part, open-label, dose-escalation Phase I trial of twice-daily oral altiratinib, with a starting dose of 15 mg, in about 50 patients with advanced solid tumors. The first part...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >